ASCO plc Newswire

ASCO plc Newswire

Comprehensive Real-Time News Feed for ASCO plc.

Results 1 - 20 of 92 in ASCO plc

  1. Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Thursday Nov 9 | Seeking Alpha

    Good afternoon and welcome to the Cyclacel Pharmaceuticals' Third Quarter 2017 Results Conference Call and Webcast. Today's call is being recorded.

    Comment?

  2. Tyme Provides Clinical and Corporate Update for the Fiscal First Half 2017Read the original story

    Wednesday Nov 8 | Customer Interaction Solutions

    Tyme Technologies, Inc. , a clinical-stage biotechnology company developing cancer therapeutics, today announced an update of its clinical and corporate progress for the first half of fiscal 2017. The Company's lead clinical program, SM-88, is a first-in-class combination therapy designed to achieve cancer cell death using cellular metabolism and oxidative stress.

    Comment?

  3. Syndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q3 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Tuesday Nov 7 | Seeking Alpha

    Good day, ladies and gentlemen, and welcome to the Syndax Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  4. Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q3 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Monday Nov 6 | Seeking Alpha

    Good day, ladies and gentlemen and welcome to the Third Quarter 2017 Earnings Call for Five Prime Therapeutics. As a reminder, this conference call maybe recorded.

    Comment?

  5. Blueprint Medicines' (BPMC) CEO Jeff Albers on Q3 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Tuesday Oct 31 | Seeking Alpha

    Good day, ladies and gentlemen, and welcome to the Q3 2017 Blueprint Medicines Corp. Earnings Conference Call. [Operator Instructions] As a reminder, this conference maybe recorded.

    Comment?

  6. What's the biggest risk for cancer - belly fat or cellphones?Read the original story w/Photo

    Tuesday Oct 24 | MSN Healthy Living

    Most Americans get the answer wrong. If you're a woman, obesity is the single biggest cause of cancer, and if you're a man, it's the second leading risk.

    Comment?

  7. What's the biggest risk for cancer - belly fat or cellphones?Read the original story w/Photo

    Tuesday Oct 24 | IVillage

    Most Americans get the answer wrong. If you're a woman, obesity is the single biggest cause of cancer, and if you're a man, it's the second leading risk.

    Comment?

  8. What's more likely to give you cancer - " belly fat or a cellphone?Read the original story w/Photo

    Tuesday Oct 24 | IVillage

    Most Americans get the answer wrong. If you're a woman, obesity is the single biggest cause of cancer, and if you're a man, it's the second leading risk.

    Comment?

  9. OncoSec Medical Presents Clinical Overview Of Comprehensive Immune...Read the original story w/Photo

    Sep 26, 2017 | BioSpace

    OncoSec Medical Presents Clinical Overview Of Comprehensive Immune Monitoring Data Demonstrating Conversion Of "Cold" Tumors To "Hot" Tumors With ImmunoPulse IL-12 And Pembrolizumab Combination Therapy /PRNewswire/ -- OncoSec Medical Incorporated , a company developing DNA-based intratumoral cancer immunotherapies, today presented an overview of the comprehensive immune monitoring data from the Phase 2 Investigator Sponsored Trial led by the at the 2nd World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies in .

    Comment?

  10. Jonathan Lewis, MD, PhD, Named a Lifetime Achiever by Marquis Who's WhoRead the original story w/Photo

    Sep 24, 2017 | 24-7 Press Release

    Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to name Jonathan Lewis, MD, PhD, a Lifetime Achiever. An accomplished listee, Dr. Lewis celebrates many years' experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field.

    Comment?

  11. Doctor Evidence To Be Subscription Software Platform For Meeting...Read the original story

    Sep 18, 2017 | Customer Interaction Solutions

    Doctor Evidence , a global health technology and consulting company, has signed a contract with the American Society of Clinical Oncology, Inc. , the world's leading professional organization representing physicians who care for people with cancer, to digitize and host ASCO meeting abstracts in DRE's technology platform. This platform will be used for in-depth queries by researchers across abstracts with the capability to track data and changing research focus in the field of oncology over time.

    Comment?

  12. Jounce Therapeutics'Read the original story w/Photo

    Sep 7, 2017 | Seeking Alpha

    So we're going to get start with our first session of the day. It's our pleasure on behalf of Wells Fargo Securities to welcome Jounce to our conference.

    Comment?

  13. Phosplatin Therapeutics Announces Collaboration With Pfizer And...Read the original story

    Sep 10, 2017 | BioSpace

    Phosplatin Therapeutics Announces Collaboration With Pfizer And Merck KGaA , Darmstadt, Germany To Evaluate Combination Of PT-112 And Avelumab In Phase I / II Studies /PRNewswire/ -- Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology drug development, announced today it has entered into a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, , to evaluate PT-112, a novel small molecule inducer of apoptosis with evidence of downstream immunogenic cell death properties, currently in Phase I development, in combination with avelumab*, a human anti-PD-L1 IgG1 monoclonal antibody.

    Comment?

  14. Internal Medicine Organizations to Explore New Options for Physicians Maintaining Board CertificationRead the original story

    Sep 8, 2017 | PR Leap

    The American Board of Internal Medicine, American College of Cardiology, American College of Physicians and American Society of Clinical Oncology announce collaboration. Philadelphia, September 8, 2017 - The American College of Cardiology , American College of Physicians and American Society of Clinical Oncology have committed to working with the American Board of Internal Medicine to explore development of collaborative pathways through which physicians can maintain board certification.

    Comment?

  15. DCVax Clinical Program Updates Presented By At Boston Scientific ConferenceRead the original story

    Sep 4, 2017 | BioSpace

    There was no webcast. Dr. Bosch has posted the PowerPoint from this presentation on the NW Bio website at www.nwbio.com Dr. Bosch's presentation reflected the breadth and consistency of NW Bio's DCVax platform and clinical programs, which include the following: 41 patient DCVax-Direct Phase I trial for 13 different solid tumor cancers, which included multi-year survival and long tails 331 patient Phase III GBM Trial, which it appears, based the trial metrics reported in the Company's industry presentation during ASCO, may include multi-year survival and a long tail; In reviewing the Phase III GBM Trial, Dr. Bosch's presentation also took note of encouraging projections by independent analysts in regard to the median overall survival and median progression free survival based on the trial metrics reported by the Company during ASCO.

    Comment?

  16. Targovax: Second Quarter And First Half 2017 ResultsRead the original story

    Aug 23, 2017 | BioSpace

    Oslo, Norway, 24 August 2017 - Targovax ASA , a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its second quarter and first half 2017 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET .

    Comment?

  17. TRACON Pharma Announces Positive Results From NCI Phase I/II Trial Of ...Read the original story

    Aug 15, 2017 | BioSpace

    TRACON Pharmaceuticals , a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive results from the National Cancer Institute Phase 1/2 trial of TRC105 and NexavarA in hepatocellular cancer were published in the August 15 issue of Clinical Cancer Research . The Phase 1b/2 trial enrolled a total of 26 patients with advanced HCC.

    Comment?

  18. Onconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q2 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Aug 15, 2017 | Seeking Alpha

    Good morning, and welcome to Onconova's Second Quarter 2017 Earnings Call and Webcast. At this time, all participants have been placed on listen-only mode.

    Comment?

  19. Jounce Therapeutics' (JNCE) CEO Richard Murray on Q2 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Aug 9, 2017 | Seeking Alpha

    Good morning, ladies and gentlemen, and welcome to Jounce Therapeutics Second Quarter 2017 earnings conference call. At this time all participants are in a listen-only mode.

    Comment?

  20. miRagen Therapeutics' (MGEN) CEO William Marshall on Q2 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Aug 11, 2017 | Seeking Alpha

    Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode.

    Comment?